Summit Therapeutics PLC Cash Flow Conversion Efficiency
Summit Therapeutics PLC cash flow conversion efficiency. Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.266x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-167.78 Million) by net assets ($629.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Summit Therapeutics PLC (2003–2025)
Cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2025. This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SMMT live share price for real-time trading data and today's change.
Summit Therapeutics PLC Cash Flow Conversion Ratio Explained
Summit Therapeutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency. Also see market value of Summit Therapeutics PLC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Krung Thai Bank Public Company Limited
F:NVPB
|
0.153x |
|
COSCO Shipping Energy Transportation Co Ltd
SHG:600026
|
0.062x |
|
Aier Eye Hospital Group
SHE:300015
|
0.069x |
|
American Homes 4 Rent
NYSE:AMH
|
0.028x |
|
The J. M. Smucker Company
NYSE:SJM
|
0.057x |
|
Alamos Gold Inc
TO:AGI
|
0.064x |
|
BitMine Immersion Technologies, Inc.
NYSE:BMNR
|
0.003x |
|
GJENSIDIGE FORSI.UNSP.ADR
F:XGJ0
|
N/A |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2025)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2025. Review Summit Therapeutics PLC free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $488.98 Million | $-239.67 Million | -0.490x | -34.08% |
| 2024-12-31 | $310.64 Million | $-113.56 Million | -0.366x | +63.00% |
| 2023-12-31 | $61.48 Million | $-60.74 Million | -0.988x | -200.93% |
| 2022-12-31 | $103.25 Million | $-33.90 Million | -0.328x | +62.33% |
| 2021-12-31 | $61.74 Million | $-53.81 Million | -0.872x | -43.93% |
| 2020-12-31 | $58.36 Million | $-35.34 Million | -0.606x | -38.80% |
| 2019-12-31 | $61.12 Million | $-26.66 Million | -0.436x | +30.67% |
| 2018-12-31 | $55.79 Million | $-35.11 Million | -0.629x | +57.26% |
| 2017-12-31 | $13.98 Million | $-20.58 Million | -1.472x | +57.64% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | +4.27% |
| 2014-12-31 | $19.53 Million | $-16.59 Million | -0.849x | +31.09% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -11.09% |
| 2011-12-31 | $3.78 Million | $-3.80 Million | -1.006x | -35.07% |
| 2010-12-31 | $5.82 Million | $-4.34 Million | -0.745x | -272.40% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.46% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.73% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -272.67% |
| 2005-12-31 | $23.38 Million | $-931.84K | -0.040x | -3655.45% |
| 2004-12-31 | $26.53 Million | $29.74K | 0.001x | +100.25% |
| 2003-12-31 | $142.31K | $-64.97K | -0.457x | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more